Bristol Myers Squibb Co. (BMY)
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Preferred: BMYMP
Company Name: |
Bristol Myers Squibb Co. |
Stock buyback: |
BMY buyback |
Website: |
www.bms.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BMY: |
125 |
Total Market Value Held by ETFs: |
$12.72B |
Total Market Capitalization: |
$96.74B |
% of Market Cap. Held by ETFs: |
13.15% |
|
|
April 19, 2024 5:41 PM Eastern
Hold (2.33 out of 4)
100th percentile
|
|